Company / EPS (Diluted)
Arrowhead Pharmaceuticals EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.92
FY2025
5-year range
-$1.92 / $0.69
FY2021-FY2025
Trend
-15.0%
vs FY2024
Sector context
#122 of 204
Health Care
What the data says
At $-1.92, Arrowhead Pharmaceuticals's eps (diluted) ranks #122 of 204 in the Health Care sector. EPS (Diluted) has declined for 4 consecutive years, from $0.69 in FY2021 to $-1.92 in FY2025.
Based on SEC 10-K filings.
-1.92 in FY2025.
Declined from $-1.36 to $-1.92 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#122 of 204 in Health CareTop 60% of 204This company -$1.92 Sector average -$0.89
▼
-116.6% below sector average
Key checks
Key Insights
- Arrowhead Pharmaceuticals's eps (diluted) has declined for 4 consecutive years.
- In FY2025, eps (diluted) decreased 15.0% year-over-year.
- Ranks #122 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.92 | -15.0% |
| FY2024 | -$1.67 | -22.8% |
| FY2023 | -$1.36 | -61.9% |
| FY2022 | -$0.84 | -221.7% |
| FY2021 | $0.69 | +206.2% |
| FY2020 | -$0.65 | -38.3% |
| FY2019 | -$0.47 | +64.9% |
| FY2018 | -$1.34 | +16.3% |
| FY2017 | -$1.60 | -28.0% |
| FY2016 | -$1.25 | +3.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026